Role for the liver X receptor agonist 22‐ketositosterol in preventing disease progression in an Alzheimer's disease mouse model
British Journal of Pharmacology · 2025
DOI: 10.1111/bph.70031 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, 2025. Verfasst von Nikita Martens und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Section Pharmacology and Vascular Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Alzheimer Disease, Liver X Receptors, Stigmasterol. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nederlandse Organisatie voor Wetenschappelijk Onderzoek, Ministry of University and Research, Alzheimer Forschung Initiative.
Themen: Demenz
Abstract (Originalsprache)
Background and Purpose Liver X receptors (LXRs) are promising therapeutic targets for alleviating Alzheimer's disease (AD) symptoms. We assessed the impact of the semi‐synthetic LXR agonist 22‐ketositosterol on disease progression in an AD mouse model. Experimental Approach From 5.5 months of age, APPswePS1ΔE9 (AD) mice and wild‐type (WT) littermates received a regular or 22‐ketositosterol‐supplemented diet (0.017% w / w ). Cognition was assessed with object location and recognition tasks and a spontaneous alternation Y‐maze test. Amyloid β was quantified using immunohistochemistry (IHC) and enzyme‐linked immunosorbent assay (ELISA), microglia (Iba1, CD68) and astrocyte (GFAP) markers using IHC. Sterols were determined in food, serum, liver and cerebellum. Key Results 22‐Ketositosterol activated both liver X receptors‐α and ‐β and promoted cholesterol efflux in cell cultures. Diet supplementation with 22‐ketositosterol prevented a decline in the performance of APPswePS1ΔE9 mice in the object location task but not in the other two tasks. Without affecting amyloid β deposition, 22‐ketositosterol decreased microglia (Iba1, CD68) and astrocyte (GFAP) markers in the cortex and hippocampus of APPswePS1ΔE9, suggesting potential anti‐inflammatory effects. No lipid accumulation was detected in the liver or serum upon 22‐ketositosterol supplementation. Conclusions and Implications Diet supplementation with 22‐ketositosterol prevented the decline in spatial memory of APPswePS1ΔE9 mice. Our data suggest therapeutic benefits of 22‐ketositosterol possibly by enhancing cholesterol efflux and mitigating inflammatory responses, without inducing hepatosteatosis or hypertriglyceridemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Section Pharmacology and Vascular Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.
- Department of Neuroscience, Biomedical Research Institute, Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium.
- Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao, China.
- Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.
- Department of Food and Drug, University of Parma, Parma, Italy.
- Department of Pharmaceutical Sciences, University of Perugia, Perugia, Italy.
ORCID-Profile: Nikita Martens, Maura Marinozzi, Dieter Lütjohann
Förderung
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- Ministry of University and Research
- Alzheimer Forschung Initiative
- Alzheimer Nederland
- Ministry of University and Research (MUR), National Recovery and Resilience Plan (NRRP)
Zitieren
APA
Martens, N., Zhan, N., Yam, S. C., Palumbo, M., Pontini, L., Leijten, F. P. J., van Vark-van der Zee, L., Voortman, G., Friedrichs, S., Gerding, A., Marinozzi, M., Jonker, J. W., Kuipers, F., Lütjohann, D., Vanmierlo, T., & Mulder, M. T. (2025). Role for the liver X receptor agonist 22‐ketositosterol in preventing disease progression in an Alzheimer's disease mouse model. British Journal of Pharmacology. https://doi.org/10.1111/bph.70031
Vancouver
Martens N, Zhan N, Yam SC, Palumbo M, Pontini L, Leijten FPJ, et al. Role for the liver X receptor agonist 22‐ketositosterol in preventing disease progression in an Alzheimer's disease mouse model. British Journal of Pharmacology. 2025. doi:10.1111/bph.70031
BibTeX
@article{Martens2025,
author = {Martens, Nikita and Zhan, Na and Yam, Sammie C and Palumbo, Marcella and Pontini, Lorenzo and Leijten, Frank P J and van Vark-van der Zee, Leonie and Voortman, Gardi and Friedrichs, Silvia and Gerding, Albert and Marinozzi, Maura and Jonker, Johan W and Kuipers, Folkert and Lütjohann, Dieter and Vanmierlo, Tim and Mulder, Monique T},
title = {Role for the liver X receptor agonist 22‐ketositosterol in preventing disease progression in an Alzheimer's disease mouse model},
journal = {British Journal of Pharmacology},
year = {2025},
doi = {10.1111/bph.70031}
}
EUVIMED